A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Exclusion Criteria

• •Patients with type 1 diabetes.
• •Exposure to semaglutide, or other Glucagon-like-peptide 1 receptor (GLP-1R) agonists (including combination products) within 3 months prior to screening, or any previous exposure to BI 456906.
• •Any additional oral anti-hyperglycemic medication beyond metformin within 3 months prior to screening.
• •Use of insulin for glycemic control within 12 months prior to screening.
• •Resting Heart Rate \>100 bpm or blood pressure ≥160/95 mmHg at screening.
• •A marked baseline prolongation of QT/QTc (Fridericia) interval or any other clinically significant Electrocardiogram (ECG) finding at screening.
• •Body weight change of +/- 5% or more in the past 3 months or on anti-obesity therapies at any time during the 6 months prior to screening.
• •Continuous oral pharmacotherapy to treat any clinical condition during the Trial. Following medications are allowed:
• •* metformin, anti-hypertensives (any medication known to cause heart block or bradycardia such as beta-blockers, verapamil and diltiazem are excluded unless used to treat heart rate control or hypertension),
• •* Hormone replacement therapy including thyroid hormone, lipid lowering, proton pump inhibitors, H2 blockers for Gastric esophageal reflux disease (GERD), analgesics,
• •* sleep medications
• •* antihistamines
• •* selective Alpha receptor blocker for benign prostatic hyperplasia Patients must be on a stable dose for at least 3 months Prior to Screening
• •Any suicidal behavior in the past 2 years, any suicidal ideation of type 4 or 5 in the Columbia-suicide severity rating scale (C-SSRS) in the past 3 months at screening.
• •Chronic or relevant acute infections.
• •Women who are pregnant, nursing, or who plan to become pregnant while in the trial.